New Hope for Retinal Degeneration: Molecule Erucamide Identified as Key Player in Natural Defense

Researchers at Scripps Research, in collaboration with UC San Diego and the Lowy Medical Research Institute, have identified the molecule erucamide as a potential player in the retina's natural response to injury.

The study was published in Nature Neuroscience on June 19, 2026.

"Erucamide does not act directly on photoreceptors but engages surrounding immune cells, supporting the neurovascular unit."

Key Findings

• Erucamide levels decrease as photoreceptor cells begin to die in preclinical models of retinal degeneration.
• Restoring erucamide via porous silicon nanoparticles activated CD11b⁺ myeloid cells in the retina.
• Erucamide binds to the protein TMEM19; reducing TMEM19 levels blocked the protective effects.
• Activated myeloid cells released signals associated with neurovascular stabilization, slowing aspects of degeneration.

Mechanism

Erucamide does not act directly on photoreceptors. Instead, it engages surrounding immune cells, supporting the neurovascular unit. This indirect action suggests a sophisticated, natural protective response already present in the body.

Implications

The findings suggest erucamide may be part of a natural protective response to retinal injury. However, further studies are needed to clarify the full pathway and explore therapeutic delivery—a challenge due to erucamide's hydrophobic nature.

Funding

The work was supported by:

• Lowy Medical Research Institute
• National Eye Institute
• California Institute for Regenerative Medicine
• National Science Foundation
• National Institutes of Health
• National Institute on Drug Abuse
• Natural Sciences and Engineering Research Council of Canada